Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Shed Price is a telehealth platform designed to make GLP-1 medications more affordable and accessible. The service emphasizes transparent pricing, typically charging $99–$199 per month (per Shed's published rates as of July 2026) for telehealth consultations and branded GLP-1 prescriptions. For patients seeking weight management or diabetes support, understanding Shed Price's cost structure and how it compares to compounded alternatives is essential.
GLP-1 receptor agonists represent a significant shift in metabolic treatment, but actual out-of-pocket costs vary widely based on insurance, pharmacy choice, and individual medication response. Shed Price addresses part of this puzzle through streamlined telehealth access. However, genetic factors—including variants in GIPR, and FTO pathways—may influence how effectively different GLP-1 formulations work for each person, potentially affecting long-term cost-effectiveness and treatment outcomes.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
How Shed Price Structures GLP-1 Access and Pricing
Shed Price operates as a subscription-based telehealth service connecting patients with licensed providers for GLP-1 evaluations and prescriptions. The platform handles initial consultations, ongoing provider communication, and prescription management, with membership typically starting around $99–$199 monthly depending on the plan selected.
The service aims to reduce barriers to GLP-1 access by eliminating lengthy in-person visits and simplifying the prescription process. Shed Price can direct prescriptions to local or mail-order pharmacies, but actual medication costs depend on the pharmacy, insurance coverage, and whether the patient receives a branded (e.g., Ozempic, Mounjaro) or compounded formulation. This distinction significantly impacts final out-of-pocket expenses.
Shed Price vs. Compounded GLP-1: Cost and Efficacy Framework
Shed Price facilitates access to branded GLP-1 medications, while compounded alternatives—like those from licensed 503A pharmacies—offer different pricing, formulations, and regulatory pathways. Neither approach guarantees superior outcomes; efficacy depends on individual biology, adherence, and clinical oversight. Comparing them requires attention to total costs, medication source, and potential genetic factors influencing response.
| Factor |
Shed Price Model |
Compounded GLP-1 (PlexusDx) |
Clinical Context |
| Telehealth Membership |
$99–$199/month |
Variable by provider model |
Covers provider consultation, prescription management |
| Medication Cost Range |
Branded scripts (varies by insurance/pharmacy) |
$129–$389/mo depending on formulation |
Compounded options often lower out-of-pocket; branded may have insurance support |
| Formulation Flexibility |
Branded semaglutide/tirzepatide options |
Semaglutide, tirzepatide, dual GLP-Squared compound |
Compounding allows dose customization; branded are fixed doses |
| Genetic Testing Available |
Not typically offered |
Precision Peptide Genetic Test ($298) reveals GIPR, FTO, MC4R variants |
Genetic context may support provider conversation about medication choice |
| Pharmacy Oversight |
Standard retail/mail-order |
Licensed 503A compounding pharmacies only |
503A compounds are state-regulated; 503B is hospital-based |
Genetic Factors That Influence GLP-1 Response and Cost-Effectiveness
Emerging evidence suggests that variants in GIPR (rs1800437), and FTO (rs9939609) pathways may influence how individual bodies respond to GLP-1 agonists. These genetic predispositions do not determine outcomes but may provide context for why one patient experiences robust weight loss while another sees a more modest response at the same dose.
If a patient receives an expensive branded GLP-1 prescription through Shed Price yet does not respond effectively, total costs accumulate quickly. Conversely, understanding genetic predispositions upfront—via a test like PlexusDx's Precision Peptide Genetic Test—can support a more informed conversation with a qualified provider about which formulation, dose, and pharmacy option might align with individual biology and budget constraints. This precision-wellness approach may improve cost-effectiveness over time.
Safety, Eligibility, and Provider Oversight
Shed Price requires providers to conduct standard medical evaluations, including screening for contraindications (history of medullary thyroid carcinoma, pancreatitis, severe kidney disease) and assessment of current medications. Compounded GLP-1 from licensed 503A pharmacies requires equivalent provider oversight; compounding does not reduce safety requirements or replace medical evaluation.
Both pathways—Shed Price's branded approach and compounded alternatives—should include ongoing provider monitoring for efficacy, tolerability, and metabolic markers. Patients should disclose all medications, medical conditions, and family history to their provider regardless of which access method they choose. Compounded formulations from 503A pharmacies are not FDA-approved as finished products but are prepared under state pharmaceutical regulations; branded options carry FDA approval for specific indications.
How PlexusDx Supports a More Personalized Approach
PlexusDx offers compounded semaglutide, tirzepatide, and dual GLP-Squared formulations from licensed 503A compounding pharmacies, providing an alternative to branded options often accessed through telehealth platforms like Shed Price. Pricing typically ranges $129/mo to $349/mo depending on formulation, dose, and platform, with potential cost advantages over branded scripts for uninsured or self-pay patients.
The Precision Peptide Genetic Test reveals predispositions in GIPR, FTO, and MC4R pathways—variants that may provide context (not certainty) about medication efficacy potential. This test does not predict exact GLP-1 response and should not replace medical evaluation; rather, it can support a more personalized conversation between patient and qualified provider about whether compounded formulations, different doses, or alternative approaches might align better with individual genetic context.
Whether a patient explores Shed Price's telehealth model, compounded alternatives, or a hybrid approach, discussing genetic predispositions and cost-effectiveness with a qualified healthcare provider ensures treatment choices are evidence-informed, affordable, and clinically appropriate. PlexusDx supports this decision-making by offering both compounded medications and genetic insight tools.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose GLP-1 Protocol is $129/mo flat. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.
Frequently Asked Questions
What exactly is Shed Price, and how does it differ from other GLP-1 telehealth platforms?
Shed Price is a subscription-based telehealth service that connects patients with licensed providers for GLP-1 evaluations and prescriptions at transparent pricing ($99–$199/month membership).
Is Shed Price more affordable than compounded GLP-1 options?
Cost depends on insurance coverage, the specific branded or compounded medication, and pharmacy choice. Shed Price's membership is transparent upfront, but final drug costs vary. Compounded alternatives from 503A pharmacies often have lower out-of-pocket costs for uninsured patients (from $189/mo for compounded semaglutide at PlexusDx).
Does PlexusDx offer a similar service to Shed Price?
PlexusDx provides compounded semaglutide, tirzepatide, and GLP-Squared formulations from licensed 503A pharmacies—an alternative medication source—rather than a telehealth membership model. PlexusDx also offers the Precision Peptide Genetic Test to support personalized treatment discussions with qualified providers.
Can genetic testing help me decide between Shed Price and compounded options?
PlexusDx's Precision Peptide Genetic Test reveals predispositions in GIPR, FTO, and MC4R pathways, which may provide context for medication response potential.
Is compounded GLP-1 from a 503A pharmacy as safe as branded options?
Compounded medications from licensed 503A pharmacies operate under state pharmaceutical regulations and require provider oversight like branded drugs. Neither approach is inherently safer; both require medical evaluation, contraindication screening, and ongoing monitoring by a qualified healthcare provider.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Shed GLP-1: Clinical Evidence, Genetic Factors, and Personalized Selection
Orderly Meds Reviews: Compounded GLP-1 Pharmacy Safety Check